AVM Biotechnology

OverviewSuggest Edit

AVM Biotechnology is a company dedicated to the discovery, development, and commercialization of stem cell-enabling technologies for regenerative medicine, immuno-oncology, and fully human biologics applications. Its lead molecule aims to replace toxic chemotherapy with a non-toxic alternative in cancer patients receiving immunotherapy and for patients undergoing allogeneic bone marrow transplant.

Latest Updates

Employees (est.) (Feb 2021)18
Cybersecurity ratingAMore

Key People/Management at AVM Biotechnology

Theresa Deisher

Theresa Deisher

Board Member
Michael J. Bernard

Michael J. Bernard

Board Member
Michael Anderson

Michael Anderson

President & Chief Administrative Officer
Peter Jarzyna

Peter Jarzyna

Lab Director
Show more

AVM Biotechnology Financials and Metrics

Summary Metrics

Founding Date


AVM Biotechnology total Funding

$8.7 m

AVM Biotechnology latest funding size

$2.84 m

Time since last funding

5 years ago
AVM Biotechnology's latest funding round in August 2016 was reported to be $2.8 m. In total, AVM Biotechnology has raised $8.7 m
Show all financial metrics

AVM Biotechnology Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

AVM Biotechnology Online and Social Media Presence

Embed Graph

AVM Biotechnology News and Updates

AVM Biotechnology President Selected to Speak at ESWI Conference in Novel and Outstanding Discoveries Track

SEATTLE, Dec. 2, 2020 /PRNewswire/ -- AVM Biotechnology, a company developing a proprietary and innovative form of dexamethasone, today announced that CEO/CSO, Dr. Theresa Deisher has been selected to present during the Novel and Outstanding Discoveries Track at the European Scientific...

Seattle AVM Biotechnology announces second IND for AVM0703: clinical trial permitted to treat COVID-19 and Influenza ARDS with its "supercharged" version of dexamethasone

SEATTLE, Sept. 16, 2020 /PRNewswire/ -- AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients. This is AVM's second...

AVM Biotechnology Expands Executive Team in Preparation for Oncology & COVID-19 Clinical Trials, Appoints Janet R. Rea, MSPH, Chief Operating Officer

SEATTLE, July 8, 2020 /PRNewswire/ -- Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill...

AVM Biotechnology Awarded SBIR Phase I Grant from National Cancer Institute

SEATTLE, June 11, 2020 /PRNewswire/ -- AVM Biotechnology has been awarded a National Cancer Institute Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH) to study the use of their lead molecule AVM0703 as a preconditioning agent to allow safe and...

AVM Biotechnology has FDA Approval for Clinical Trials for Promising New Cancer Treatment

SEATTLE, April 14, 2020 /PRNewswire/ -- Seattle's AVM Biotechnology announces clinical trial approval for AVM0703, an exciting new drug to treat terminal no-option Non-Hodgkins Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia. We are seeking patients to begin Phase...

AVM Biotechnology Frequently Asked Questions

  • When was AVM Biotechnology founded?

    AVM Biotechnology was founded in 2008.

  • Who are AVM Biotechnology key executives?

    AVM Biotechnology's key executives are Theresa Deisher, Michael J. Bernard and Michael Anderson.

  • How many employees does AVM Biotechnology have?

    AVM Biotechnology has 18 employees.

  • Who are AVM Biotechnology competitors?

    Competitors of AVM Biotechnology include Ironwood Pharmaceuticals, Biogen and MyoKardia.